

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMedline reloaded with enhancements
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:04:13 ON 20 FEB 2008

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:04:24 ON 20 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2008 HIGHEST RN 1004621-14-0
DICTIONARY FILE UPDATES: 19 FEB 2008 HIGHEST RN 1004621-14-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	0.67

FILE 'REGISTRY' ENTERED AT 09:04:55 ON 20 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2008 HIGHEST RN 1004621-14-0
DICTIONARY FILE UPDATES: 19 FEB 2008 HIGHEST RN 1004621-14-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> e hydroxymethylfurfural

E1	1	HYDROXYMETHYLFURATRIZINE/BI
E2	3	HYDROXYMETHYLFURFUR/BI
E3	2 -->	HYDROXYMETHYLFURFURAL/BI
E4	1	HYDROXYMETHYLFURFURALALDEHYDE/BI
E5	1	HYDROXYMETHYLFURFURALDEHYDE/BI
E6	1	HYDROXYMETHYLFURFUROL/BI
E7	1	HYDROXYMETHYLFURFURYL/BI
E8	1	HYDROXYMETHYLFURME/BI
E9	1	HYDROXYMETHYLFURMETHI/BI
E10	1	HYDROXYMETHYLFURMETHIDE/BI
E11	2	HYDROXYMETHYLFURO/BI
E12	1	HYDROXYMETHYLGLUTAM/BI

=> s e3

L1 2 HYDROXYMETHYLFURFURAL/BI

=> d l1 1-2


L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 25376-49-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Furancarboxaldehyde, (hydroxymethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Furaldehyde, (hydroxymethyl)- (7CI, 8CI)
OTHER NAMES:
CN Hydroxymethylfurfural
MF C6 H6 O3
CI IDS, COM
LC STN Files: AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS,
CASREACT, DDFU, DETHERM*, DRUGU, EMBASE, IPA, PIRA, PROMT, TOXCENTER,
USPATOLD
(*File contains numerically searchable property data)



D1-CH₂-OH

333 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 333 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 67-47-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2-Furaldehyde, 5-(hydroxymethyl)- (8CI)
 OTHER NAMES:
 CN 2-Hydroxymethyl-5-furfural
 CN 5-(Hydroxymethyl)-2-furaldehyde
 CN 5-(Hydroxymethyl)-2-furancarboxal
 CN 5-(Hydroxymethyl)-2-furancarboxaldehyde
 CN 5-(Hydroxymethyl)-2-furfural
 CN 5-(Hydroxymethyl)-2-furfuraldehyde
 CN 5-(Hydroxymethyl)furfural
 CN 5-Hydroxymethyl-2-formylfuran
 CN 5-Hydroxymethylfuraldehyde
 CN 5-Hydroxymethylfuran-2-aldehyde
 CN 5-Hydroxymethylfurfuraldehyde
 CN 5-Hydroxymethylfurfural
 CN 5-Oxymethylfurfural
 CN HMF
 CN Hydroxymethylfurfural
 CN Hydroxymethylfurfuralaldehyde
 CN Hydroxymethylfurfuraldehyde
 CN NSC 40738
 DR 76330-16-0
 MF C6 H6 O3
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, EMBASE, GMLIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3100 REFERENCES IN FILE CA (1907 TO DATE)

36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3109 REFERENCES IN FILE CAPLUS (1907 TO DATE)
51 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e alphaketoglutaric

E1 1 ALPHAIV/BI
E2 1 ALPHAJEL/BI
E3 0 --> ALPHAKETOGLUTARIC/BI
E4 1 ALPHAKIL/BI
E5 3 ALPHAL/BI
E6 2 ALPHALB/BI
E7 1 ALPHALIN/BI
E8 2 ALPHALOY/BI
E9 1 ALPHALUX/BI
E10 4 ALPHAM/BI
E11 7 ALPHAM1/BI
E12 1 ALPHAMAL/BI

=> s 328-50-7

L2 1 328-50-7
(328-50-7/RN)

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 328-50-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pentanedioic acid, 2-oxo- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutaric acid, 2-oxo- (8CI)

OTHER NAMES:

CN α -keto-Glutaric acid

CN α -Ketoglutaric acid

CN α -Oxoglutaric acid

CN α -Oxopentanedioic acid

CN 2-Ketoglutaric acid

CN 2-Oxo-1,5-pentanedioic acid

CN 2-Oxoglutaric acid

CN 2-Oxopentanedioic acid

CN NSC 17391

DR 27175-99-1

MF C5 H6 O5


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8979 REFERENCES IN FILE CA (1907 TO DATE)
166 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8997 REFERENCES IN FILE CAPLUS (1907 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e dehydroascorbic

E1	1	DEHYDROASCORBATE/BI
E2	124	DEHYDROASCORBATE/BI
E3	23 -->	DEHYDROASCORBIC/BI
E4	1	DEHYDROASCRO/BI
E5	1	DEHYDROASCROBI/BI
E6	1	DEHYDROASCROBIC/BI
E7	3	DEHYDROASIMILO/BI
E8	3	DEHYDROASIMILOBI/BI
E9	3	DEHYDROASIMIOBINE/BI
E10	1	DEHYDROASPART/BI
E11	1	DEHYDROASPARTAME/BI
E12	2	DEHYDROASPARTIC/BI

=> s e3

L3 23 DEHYDROASCORBIC/BI

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.60	19.27

FILE 'CAPLUS' ENTERED AT 09:08:09 ON 20 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 19 Feb 2008 (20080219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s (l1 or hmf of hydroxymethylfurfur?) and (l2 or ketoglut?) and ?methionine
3362 L1
1257 HMF
29 HMFS
1275 HMF
(HMF OR HMFS)
2447 HYDROXYMETHYL FURFUR?
17 HMF OF HYDROXYMETHYL FURFUR?

(HMF(1W)HYDROXYMETHYLFURFUR?)

8997 L2
13225 KETOGLUT?
101086 ?METHIONINE

L4 1 (L1 OR HMF OF HYDROXYMETHYLFURFUR?) AND (L2 OR KETOGLUT?) AND
?METHIONINE

=> d 14

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on SIN
AN 2004:467738 CAPLUS
DN 141:17591
TI Agent having a destructive effect on malignant tumors and method for the
production
IN Groke, Karl; Herwig, Ralf
PA C.Y.L. Handelsoges. m.b.H., Austria; Ferdinand, Peter
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047832	A1	20040610	WO 2003-EP50712	20031013
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AT 2002001778	A	20040815	AT 2002-1778	20021127
AT 412447	B	20050325		
CA 2507273	A1	20040610	CA 2003-2507273	20031013
AU 2003285351	A1	20040618	AU 2003-285351	20031013
EP 1565176	A1	20050824	EP 2003-778338	20031013
EP 1565176	B1	20060524		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508998	T	20060316	JP 2004-554531	20031013
AT 326958	T	20060615	AT 2003-778338	20031013
PT 1565176	T	20061031	PT 2003-778338	20031013
ES 2268452	T3	20070316	ES 2003-778338	20031013
US 2006292218	A1	20061228	US 2006-536777	20060907
FRAI AT 2002-1778	A	20021127		
EP 2003-778338	A	20031013		
WO 2003-EP50712	W	20031013		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (l1 or hmf of hydroxymethylfurfur?) and (l2 or ketoglut?)

3362 L1
1257 HMF
29 HMFS
1275 HMF

(HMF OR HMFS)

2447 HYDROXYMETHYLFURFUR?
17 HMF OF HYDROXYMETHYLFURFUR?

(HMF(1W)HYDROXYMETHYLFURFUR?)

8997 L2

13225 KETOGLUT?

L5 10 (L1 OR HMF OF HYDROXYMETHYLFURFUR?) AND (L2 OR KETOGLUT?)

=> d 15 ibib abs 1-10

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1140948 CAPLUS

DOCUMENT NUMBER: 147:420129

TITLE: Use of α -ketoglutaric acid and 5-hydroxymethylfurfural for reducing oxidative stress

INVENTOR(S): Moser, Peter Michael; Greilberger, Joachim; Maier, Alfred; Juan, Heinz; Buecherl-Harrer, Christian; Kager, Ernst

PATENT ASSIGNEE(S): C.Y.L. Pharmazeutika GmbH, Austria

SOURCE: Eur. Pat. Appl., 7pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1842536	A1	20071010	EP 2007-104493	20070320
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
AT 503385	A1	20071015	AT 2006-464	20060320
PRIORITY APPLN. INFO.:			AT 2006-464	A 20060320
AB The invention discloses the use of α -ketoglutaric acid and 5-hydroxymethylfurfural for the preparation of a medicament for the treatment and prevention of oxidative stress in humans and animals, particularly for the reduction of reactive oxygen and nitrogen species and simultaneously increasing antioxidant capacity. The compds. of the invention can be used for the improvement of general conditions and improving performance.				
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:758613 CAPLUS

DOCUMENT NUMBER: 147:197593

TITLE: Using tolerance intervals in pre-study validation of analytical methods to predict in-study results

AUTHOR(S): Rozet, Eric; Hubert, Cedric; Ceccato, Attilio; Dewe, Walther; Ziemons, Eric; Moonen, Francois; Michail, Karim; Wintersteiger, Reinhold; Streel, Bruno; Boulanger, Bruno; Hubert, Philippe

CORPORATE SOURCE: Laboratory of Analytical Chemistry, Bioanalytical Chemistry Research Unit, Institute of Pharmacy, CHU, University of Liege, Liege, B-4000, Belg.

SOURCE: Journal of Chromatography, A (2007), 1158(1-2), 126-137

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB It is recognized that the purpose of validation of anal. methods is to demonstrate that the method is suited for its intended purpose. Validation is not only required by regulatory authorities, but is also a decisive phase before the routine use of the method. For a quant. anal.

method the objective is to quantify the target analytes with a known and suitable accuracy. For that purpose, first, a decision about the validity of the method based on prediction is proposed: a method is declared proper for routine application if it is considered that most of the future results generated will be accurate enough. This can be achieved by the " β -expectation tolerance interval" (accuracy profile) as the decision tool to assess the validity of the anal. method. Moreover, the concept of "fit-for-purpose" is also proposed here to select the most relevant response function as calibration curve, i.e. choosing a response function based solely on the predicted results this model will allow to obtain. This paper reports 4 case studies where the results obtained with quality control samples in routine were compared to predictions made in the validation phase. Predictions made using the " β -expectation tolerance interval" are shown to be accurate and trustful for decision making. It is therefore suggested that an adequate way to conciliate both the objectives of the anal. method in routine anal. and those of the validation step consists in taking the decision about the validity of the anal. method based on prediction of the future results using the most appropriate response function curve, i.e. the fit-for-future-purpose concept.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2006:1326164 CAPLUS

DOCUMENT NUMBER: 146:134507

TITLE: Development and validation of a liquid chromatographic method for the determination of hydroxymethylfurfural and alpha-ketoglutaric acid in human plasma
 AUTHOR(S): Michail, K.; Juan, H.; Maier, A.; Matzi, V.; Greilberger, J.; Wintersteiger, R.

CORPORATE SOURCE: Institute of Pharmaceutical Sciences, University of Graz, Austria

SOURCE: Analytica Chimica Acta (2007), 581(2), 287-297
 CODEN: ACACAM; ISSN: 0003-2670

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hydroxymethylfurfural (HMF) and alpha-ketoglutaric acid (KG) have been recently investigated as potential cancer cell damaging agents. We herein report for the first time a validated quant. assay for their simultaneous determination in human plasma which is amenable to be applied in

the future screening of the target compds. in human probands in order to properly design a targeted chemotherapeutic regimen for certain types of malignant tumors. A simple liquid chromatog. method in conjunction to derivatization after a two-step optimized solid phase clean-up procedure is described. The method is based on the reaction of HMF and KG with 2-nitrophenylhydrazine or 2,4-dinitrophenylhydrazine in an aqueous environment. Reaction conditions were studied with respect to pH, reagent volume, reaction temperature and time. Exact testing of such parameters beside careful selection of the mobile phase composition rendered feasible the quantification of the chemical significantly differing analytes along a single chromatog. run. The formed derivs. could be separated isocratically by reversed-phase LC on a C8-column. Detection in the UV and in the visible range is possible. Results showed good recovery and reproducibility with detection limits ($S/N = 3$) down to 2 pmol analyte on column. Resolution of the syn and anti geometric isomers of the HMF and KG derivs. is possible. The isomeric ratio in relation to the reaction pH is discussed.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:467738 CAPLUS
 DOCUMENT NUMBER: 141:17591
 TITLE: Agent having a destructive effect on malignant tumors and method for the production
 INVENTOR(S): Groke, Karl; Herwig, Ralf
 PATENT ASSIGNEE(S): C.Y.L. Handelsges. m.b.H., Austria; Ferdinand, Peter
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047832	A1	20040610	WO 2003-EP50712	20031013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AT 2002001778	A	20040815	AT 2002-1778	20021127
AT 412447	B	20050325		
CA 2507273	A1	20040610	CA 2003-2507273	20031013
AU 2003285351	A1	20040618	AU 2003-285351	20031013
EP 1565176	A1	20050824	EP 2003-778338	20031013
EP 1565176	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508998	T	20060316	JP 2004-554531	20031013
AT 326958	T	20060615	AT 2003-778338	20031013
PT 1565176	T	20061031	PT 2003-778338	20031013
ES 2268452	T3	20070316	ES 2003-778338	20031013
US 2006292218	A1	20061228	US 2006-536777	20060907
PRIORITY APPLN. INFO.: AT 2002-1778 A 20021127 EP 2003-778338 A 20031013 WO 2003-EP50712 W 20031013				
AB Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can be used in the form of an infusion, in an oral or rectal form of administration, or as an irrigation in cancer therapy. The treatment of cancer patients with the following infusion solution is reported: a- ketoglutaric acid 9.0 g/L; 5-hydroxymethyl furfural 3.0 g/L; N-acetyl-seleno-L-methionine 2.0 mg/L; N-acetyl-L-methionine 100.0 mg/L; glucose 30.0 g/L; sodium and potassium ions to set pH. REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:909147 CAPLUS
 DOCUMENT NUMBER: 139:369764
 TITLE: Composition for the treatment of alcohol and smoking

dependence using 5-hydroxymethylfurfural-containing drinks
 Groke, Karl; Kager, Ernst; Buecherl, Christian
 INVENTOR(S): Austria
 PATENT ASSIGNEE(S): Eur. Pat. Appl., 4 pp.
 SOURCE: CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1362586	A1	20031119	EP 2003-450035	20030205
EP 1362586	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 200200764	A	20031015	AT 2002-764	20020517
AT 411730	B	20040525		
AT 303806	T	20050915	AT 2003-450035	20030205
ES 2252651	T3	20060516	ES 2003-450035	20030205
CA 2486298	A1	20031127	CA 2003-2486298	20030515
WO 2003097032	A1	20031127	WO 2003-AT140	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003232906	A1	20031202	AU 2003-232906	20030515
JP 2005528419	T	20050922	JP 2004-505031	20030515
US 2005274391	A1	20051215	US 2005-514775	20050113
PRIORITY APPLN. INFO.: AT 2002-764 A 20020517 EP 2003-450035 A 20030205 WO 2003-AT140 W 20030515				
AB The invention concerns the treatment of alc. and smoking dependence by administering a drink that contains per L (g): α -ketoglutaric acid 4-8; 5-hydroxymethylfurfural 0.2-0.6; saccharose 20-40; sodium bicarbonate 2.5-5.0; sorbic acid 0.3-0.8; optionally citric acid 0.5.				
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				
L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN				
ACCESSION NUMBER: 1998:512775 CAPLUS				
DOCUMENT NUMBER: 129:148301				
TITLE: Volatile Compounds Involved in the Aroma of Sweet Fortified Wines (Vins Doux Naturels) from Grenache Noir				
AUTHOR(S): Schneider, R.; Baumes, R.; Bayonove, C.; Razungles, A.				
CORPORATE SOURCE: Laboratoire des Aromes et Substances Naturelles, IPV-ENSAM-INRA, Montpellier, 34060, Fr.				
SOURCE: Journal of Agricultural and Food Chemistry (1998), 46(8), 3230-3237 CODEN: JAFCAU; ISSN: 0021-8561				
PUBLISHER: American Chemical Society				
DOCUMENT TYPE: Journal				
LANGUAGE: English				

AB A typical com. sample of red Vins Doux Naturels (VDN), Maury 1991, was analyzed by liquid-liquid extraction with dichloromethane followed by chromatog.

anal. by GC/FID, GC/MS, and GC/sniffing. GC/sniffing using a DB-Wax and a DB-5 fused silica capillary column revealed five substances having odors corresponding to the aromas of these sweet fortified wines: an enolic lactone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone or sotolone; an acetal, trans-2-methyl-5-hydroxy-1,3-dioxane; and three Et esters, 4-carbethoxy- γ -butyrolactone, Et 2-hydroxyglutarate, and Et pyroglutamate. The last four compds. were synthesized and their olfactory characteristics checked under the same conditions, which confirmed the odors revealed for the natural compds. except for trans-2-methyl-5-hydroxy-1,3-dioxane, which exhibited no odor. Furthermore, five other sweet fortified wines subjected to different types of oxidative aging were analyzed to quant. determine the four identified aroma compds. The three Et esters were found in these wines at different levels increasing with oxidative aging. However, sotolone could not be detected. In addition, other volatile compds. from the six wines were analyzed. The levels of polar Et esters and the related lactones, the carbonyl compds., and their acetals increased in the wines after oxidative aging as well.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1985:77413 CAPLUS
DOCUMENT NUMBER: 102:77413
ORIGINAL REFERENCE NO.: 102:12135a,12138a
TITLE: Polar carbonyls in cow and buffalo ghee
AUTHOR(S): Rao, D. Vijayender; Ramamurthy, M. K.
CORPORATE SOURCE: Southern Reg. Stn., Natl. Dairy Res. Inst., Bangalore, 560030, India
SOURCE: Indian Journal of Dairy Science (1984), 37(2), 98-102
CODEN: IJDSAI; ISSN: 0019-5146
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Polar carbonyls (PC) were isolated as their 2,4-DNP hydrazones from ghee and estimated. Ghee prepared at clarification temps. of 100° and 120° for 10 min. contained .apprx.1.9 and 31.5 mg of PC resp. in the case of fresh cream, 6.1 and 75.8 mg in the case of acid cream, and 1.4 and 3.2 mg/100 g ghee in the case of butter. Sepns. of 2,4-DNP hydrazones of total PC of ghee clarified at 100° by TLC showed 6 components. Three of them were tentatively identified as diacetyl [431-03-8], methyl glyoxal [78-98-8], and α -ketoglutaric acid [328-50-7]. The PC of ghee clarified at 120° showed 10 components. Among them, in addition to the 3 above were, furfural [98-01-1] and hydroxy Me furfural [25376-49-2] were also tentatively identified.

L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 1984:185071 CAPLUS
DOCUMENT NUMBER: 100:185071
ORIGINAL REFERENCE NO.: 100:28001a,28004a
TITLE: High-performance liquid chromatographic elution behavior of alcohols, aldehydes, ketones, organic acids and carbohydrates on a strong cation-exchange stationary phase
AUTHOR(S): Pecina, R.; Bonn, G.; Burtcher, E.; Bobleter, O.
CORPORATE SOURCE: Inst. Radiochem., Univ. Innsbruck, Innsbruck, Austria
SOURCE: Journal of Chromatography (1984), 287(2), 245-58
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The high-performance liquid chromatog. separation of alcs., aldehydes, ketones, carboxylic acids, and carbohydrates on a polystyrene-based strong cation-exchange resin is described. The column temperature was a very important parameter for optimizing sepns. of these substances. The effect of different functional groups on the elution behavior is discussed.

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:548868 CAPLUS
DOCUMENT NUMBER: 95:148868
ORIGINAL REFERENCE NO.: 95:24905a,24908a
TITLE: Aroma of Balady bread. 1. Determination of carbonyl components
AUTHOR(S): El-Samahy, S. K.; Elias, A. N.; Askar, A.
CORPORATE SOURCE: Fac. Agric., Univ. Zagazig, Zagazig, Egypt
SOURCE: Getreide, Mehl und Brot (1981), 35(7), 182-4
CODEN: GEMBAN; ISSN: 0367-4177
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Balady bread, fermented dough, and dough fresh from mixing were homogenized with H₂O (200 g in 200 mL), extracted with CHCl₃, treated with 2,4-dinitrophenylhydrazine in 2N HCl to derivatize the carbonyls, and the dinitrophenylhydrazones were separated by paper chromatog. The carbonyl compds. were determined by reaction gas chromatog. with α -ketoglutaric acid at 250° to liberate free carbonyls in the precolumn for separation on a 20% Carbowax 20M on Chromosorb P (35-80 mesh) column. Fourteen of the 27 compds. separated were identified, 12 aldehydes and 2 ketones. Most of the carbonyls formed during dough fermentation. Two unidentified compds. were >63% of the carbonyls in unfermented dough, one of which increased to 48% of the total and the other nearly disappeared during fermentation; both compds. were absent from bread. The major carbonyls in baked bread were propanal [123-38-6], acetone [67-64-1], and 2-methylpentanal [123-15-9].

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1964:457866 CAPLUS
DOCUMENT NUMBER: 61:57866
ORIGINAL REFERENCE NO.: 61:10047c-f
TITLE: Determination of furan aldehydes. Reaction with aniline in acetic and hydrochloric acid solutions
AUTHOR(S): Friedemann, Theodore E.; Keegan, Patricia K.; Witt, Norman F.
CORPORATE SOURCE: Univ. of Colorado, Boulder
SOURCE: Analytical Biochemistry (1964), 8(3), 300-11
CODEN: ANBCA2; ISSN: 0003-2697
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Procedures are described for the spectrophotometric determination of 1-7 y furfural, methylfurfural (MF), and (hydroxymethyl)furfural (HMF) per mL. solution by a combination of several methods: direct spectrophotometry, mixing equal vols. of sample solution and 10% PhNH₂ in 80% HOAc, and by mixing equal vols. of sample solution and 10% PhNH₂ in .apprx.0.9N excess HCl. Absorbances are determined at specified wavelengths, depending upon the type of sample analyzed. ϵ and λ maximum of furan aldehydes were determined under uniform conditions in 0.001N HCl: furfural, 3.54 + 103 at 229 m μ and 15.375 + 103 at 277 m μ ; MF, 2.98 + 103 at 228 m μ and 16.22 + 103 at 291.5 m μ ; HMF, 3.605 + 103 at 229 m μ and 16.75 + 103 at 284 m μ . Data were obtained under the same uniform conditions on furfuryl alc. furoic acid, furoin, furil, Me₂CO, acetol, methylglyoxal, pyruvic acid, levulinic acid, α -ketoglutaric acid, diacetyl, actylacetone, and acetylacetone. None of these compds., even if present in equimolar concentration, except furoin

and acetylacetone, interferes significantly in the determination of furan aldehydes. Reductic acid may interfere. At pH 7.4, ϵ was 20.705 + 103 at λ maximum 281 m μ ; in 0.0002-1.0N acid, ϵ and λ maximum were essentially unchanged, 13.79 + 103 (average) at 263 m μ . Oxidation to dehydroreductic acid completely removes the possible interference. The reaction with 10% PhNH₂ in 80% HOAc is highly sensitive for all 3 aldehydes. Furfural gave no absorption peak in the ultraviolet. The reaction with 10% PhNH₂ in HCl is also highly sensitive, especially for MF. ϵ and λ maximum were: for furfural, 7.575 + 103 352 m μ ; for MF, 11.75 + 103 at 370 m μ ; for HMF, 8.22 + 103 at 363 m μ . A distillation procedure is described for separating furfural and

MF

from HMF in which 98-99% furfural and MF, and less than 1% HMF, were recovered in the distillate.

=> s methionine (s) (cancer or tumor or neoplasm)

93475 METHIONINE
545 METHIONINES
93665 METHIONINE
(METHIONINE OR METHIONINES)
348164 CANCER
51197 CANCERS
361109 CANCER
(CANCER OR CANCERS)
440912 TUMOR
165946 TUMORS
492219 TUMOR
(TUMOR OR TUMORS)
483382 NEOPLASM
37012 NEOPLASMS
500298 NEOPLASM
(NEOPLASM OR NEOPLASMS)

L6 1415 METHIONINE (S) (CANCER OR TUMOR OR NEOPLASM)

=> s l6 and derivative

56250 DERIVATIVE
352679 DERIVATIVES
404710 DERIVATIVE
(DERIVATIVE OR DERIVATIVES)
656133 DERIV
1168486 DERIVS
1537343 DERIV
(DERIV OR DERIVS)
1642194 DERIVATIVE
(DERIVATIVE OR DERIV)

L7 122 L6 AND DERIVATIVE

=> d scan

L7 122 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K037-14

INCL 514006000

CC 1-6 (Pharmacology)

Section cross-reference(s): 63

TI Method for the inhibition of the proliferation of cancer cells by injection into the tumor of a selenodithiol

ST selenodithiol cancer treatment; selenodiglutathione lung adenocarcinoma inhibition; neoplasm inhibitor selenodithiol

IT Neoplasm inhibitors
(selenodithiols as)

IT Lung, neoplasm

(adenocarcinoma, inhibitors, selenodithiols)

IT Neoplasm inhibitors
(colon adenocarcinoma, selenodithiols)

IT Intestine, neoplasm
(colon, adenocarcinoma, inhibitors, selenodithiols)

IT Thiols, compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-, selenium complexes, neoplasm inhibitors)

IT Neoplasm inhibitors
(glioma, selenodithiols)

IT Skin
(keratinocyte, inhibitors of, selenodithiols as)

IT Neoplasm inhibitors
(lung adenocarcinoma, selenodithiols)

IT Neoplasm inhibitors
(mammary gland adenocarcinoma, selenodithiols)

IT Neoplasm inhibitors
(medulloblastoma, selenodithiols)

IT Brain, neoplasm
(medulloblastoma, inhibitors, selenodithiols)

IT Neoplasm inhibitors
(melanoma, selenodithiols)

IT Mammary gland
(neoplasm, adenocarcinoma, inhibitors, selenodithiols)

IT Neuroglia
(neoplasm, inhibitors, selenodithiols)

IT 63-68-3D, L-Methionine, selenium derivs. 7782-49-2D,
Selenium, methionine derivs. 20710-99-0,
Selenodicycysteine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibitor)

IT 33944-90-0P, Selenodiglutathione
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for neoplasm inhibitor)

IT 10102-18-8, Sodium selenite
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with reduced glutathione)

IT 70-18-8D, Glutathione, reduced
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with sodium selenite)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 09:04:13 ON 20 FEB 2008)

FILE 'REGISTRY' ENTERED AT 09:04:24 ON 20 FEB 2008

FILE 'REGISTRY' ENTERED AT 09:04:55 ON 20 FEB 2008

E HYDROXYMETHYLFURFURAL

L1 2 S E3

E ALPHAKETOGLUTARIC

L2 1 S 328-50-7

E DEHYDROASCORBIC

L3 23 S E3

FILE 'CAPLUS' ENTERED AT 09:08:09 ON 20 FEB 2008

L4 1 S (L1 OR HMF OF HYDROXYMETHYLFURFUR?) AND (L2 OR KETOGLUT?) AND
 L5 10 S (L1 OR HMF OF HYDROXYMETHYLFURFUR?) AND (L2 OR KETOGLUT?)
 L6 1415 S METHIONINE (S) (CANCER OR TUMOR OR NEOPLASM)
 L7 122 S L6 AND DERIVATIVE

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
61.99	81.26

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.00	-8.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:15:42 ON 20 FEB 2008